Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.

Joong-Won, Park,; Yoon Jun, Kim,; Do Young, Kim,; Si-Hyun, Bae,; Seung Woon, Paik,; Youn-Jae, Lee,; Hwi Young, Kim,; Han Chu, Lee,; Sang Young, Han,; Jae Youn, Cheong,; Oh Sang, Kwon,; Jong Eun, Yeon,; Bo Hyun, Kim,; Jaeseok, Hwang,

doi:10.1016/j.jhep.2018.11.029

Public

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.

Published in Journal of hepatology • Apr 1, 2019

Authors:

Park, Joong-Won

Kim, Yoon Jun

Kim, Do Young

Abstract

BACKGROUND & AIMS: Sorafenib is first-line standard of care for patients with advanced hepatocellular carcinoma (HCC), yet it confers limited survival benefit. Therefore, we aimed to compare clinical outcomes of sorafenib combined with concurrent conventional transarterial chemoembolization (cTACE) ...

Subject

Combination treatment

Hepatocellular carcinoma

Sorafenib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!